Hydroxyellipticine-1a, with the CAS number 109628-38-8, is a synthetic derivative of ellipticine, a compound known for its potential anticancer properties. This substance features a hydroxyl group, which enhances its solubility and biological activity compared to its parent compound. Hydroxyellipticine-1a exhibits a complex polycyclic structure, contributing to its interaction with DNA and potential inhibition of topoisomerase enzymes, which are crucial for DNA replication and transcription. The compound has been studied for its pharmacological effects, particularly in cancer research, where it shows promise as an antitumor agent. Its mechanism of action may involve the induction of apoptosis in cancer cells and the modulation of various signaling pathways. Additionally, the presence of the hydroxyl group may influence its pharmacokinetics, including absorption, distribution, metabolism, and excretion. Overall, Hydroxyellipticine-1a represents a significant interest in medicinal chemistry, particularly in the development of novel therapeutic agents targeting cancer.

Hydroxyellipticine-1a is a novel selective r(CGG)exp probe, improving pre-mRNA splicing defects, inhibiting formation of nuclear inclusions and RANT in a FXTAS cellular mode.l

Hydroxyellipticine-1a

109628-38-8: Hydroxyellipticine-1a, with the CAS number 109628-38-8, is a synthetic derivative of ellipticine, a compound known for its potential anticancer properties. This substance features a hydroxyl group, which enhances its solubility and biological activity compared to its parent compound. Hydroxyellipticine-1a exhibits a complex polycyclic structure, contributing to its interaction with DNA and potential inhibition of topoisomerase enzymes, which are crucial for DNA replication and transcription. The compound has been studied for its pharmacological effects, particularly in cancer research, where it shows promise as an antitumor agent. Its mechanism of action may involve the induction of apoptosis in cancer cells and the modulation of various signaling pathways. Additionally, the presence of the hydroxyl group may influence its pharmacokinetics, including absorption, distribution, metabolism, and excretion. Overall, Hydroxyellipticine-1a represents a significant interest in medicinal chemistry, particularly in the development of novel therapeutic agents targeting cancer.

Hydroxyellipticine-1a corrects pre-mRNA splicing, prevents nuclear inclusions, and reduces RANT in FXTAS cells.

CAS 109628-38-8

Hydroxyellipticine-1a

Hydroxyellipticine-1a

Ref: TM-T27562